Sharp Therapeutics Corp.
SHRX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Net Income | -59.73% | 130.97% | -164.60% | 27.68% | |
| Total Depreciation and Amortization | 472.73% | 177.11% | -36.26% | -83.21% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 388.82% | -397.03% | 218.69% | -96.05% | |
| Change in Net Operating Assets | 36.95% | -94.67% | -323.89% | -432.75% | |
| Cash from Operations | -28.50% | -98.25% | -132.03% | -86.98% | |
| Capital Expenditure | -- | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -- | -- | -- | -- | |
| Total Debt Issued | -- | -- | -- | 248.18% | |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | |
| Issuance of Common Stock | -- | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | -- | 102.68% | -111.11% | -100.00% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -4,008.11% | 2,873.49% | -710.71% | -14.20% | |